
VOTIS Subdermal Imaging Raises US$2.5 Million
Jerusalem based VOTIS Subdermal Imaging Technologies, Ltd. has raised US$2.5 million in a private placement of equity to a consortium of investors in Israel, Italy,

Memorial Hermann Health System Former President & CEO, Dan Wolterman, appointed BactoByte Chair
BactoByte has appointed Mr. Dan Wolterman, Former President and CEO of Memorial Hermann Health System, as a Board Chair. With more than 40 years of

Respinova Granted FDA 510(k) Clearance for Pulsehaler
Respinova has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Pulsehaler™. Pulsehaler™ is an innovative device that facilitates the opening

KAHR’s Anti-CD47 in Blood Cancers Clinical Trials Funded by Texas MD Anderson Cancer Focus Fund
KAHR, a Jerusalem based clinical-stage cancer immunotherapy company developing novel bi-functional fusion proteins, and Cancer Focus Fund, LP, a unique venture capital fund established in

Jerusalem Startup eggXYt Launches Bid to Disrupt The Egg Industry
eggXYt, a Jerusalem-based genetic tech startup, is developing technology to save billions of baby chickens from unnecessary death, while generating significant savings for farmers. eggXYt

SpliSense Raises $28.5 Million for Treatment of CF
Jerusalem-based biopharmaceutical company SpliSense, which is developing transformative mRNA-altering therapies for cystic fibrosis (CF) and other genetic pulmonary diseases, announced on Thursday the closing of

Smoking Cessation Becomes BrainsWay’s 3rd Noninvasive Brain Disorder Treatment
BrainsWay Ltd., a global leader in advanced noninvasive treatment of brain disorders, has started the distribution of its first 10 Deep Transcranial Magnetic Stimulation (Deep

Purple Biotech Initiates Phase 1b/2 Clinical Trial of CM24 Therapy for Non-Small Cell Lung Cancer & Pancreatic Cancer
Purple Biotech Ltd. (“Purple Biotech”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today

Oramed JV, Oravax Medical, & India’s Premas Biotech to Develop Oral COVID-19 Vaccines
Jerusalem’s clinical-stage pharmaceutical company Oramed Pharmaceuticals is forming a joint venture with Premas Biotech , a biotechnology firm based in Gurugram, India, to develop novel oral